Prof. Olivier DANOS
Prof. Danos is a Research Director at the CNRS. He completed his PhD studies in Virology and Molecular Biology at the Pasteur Institute. With Dr. Richard Mulligan at the Whitehead Institute, he developed retroviral vectors for gene transfer.
At the Pasteur Institute in 1989, he directed the laboratory of “Retrovirus et Transfert Génétique”. He was the Scientific Director of Généthon between 1998 and 2005. He is a member of the INSERM U781 at the “Necker Enfants Malades Hospital” (Paris) and the Director of Gene Therapy Consortium at UCL (London). He sits on several international peer review and expert committees on gene therapy and virology, and has authored over 200 publications in these fields. He is a founding member of the European Society of Gene Therapy (ESGT) and was elected as its president in 1996. Prof. Danos has also served as Senior Scientific Director of Somatix Therapy Corporation.
Prof. Pierre-Simon ROHRLICH
Prof. Rohrlich graduated as MD in pediatry in 1991 and practiced as an associate professor in Pediatric hemato-immunology at Robert-Debré Hospital in Paris where he specialized in hematopoietic stem cell transplantation.
In 1995, he obtained his diploma in Transfusion Medicine and Immunohematology (DESC). After his PhD of Immunology at Pasteur Institute in 2003, he worked on human CMV infections and on the role of HFE molecules in human physiopathology. His pioneer results on the immune aspects of HFE have been acknowledged worldwide. He has been accredited as research director, and appointed as Professor in Pediatric hematology (PU-PH) at University of Franche-Comté. He is a member of the French National Bio-vigilance committee, lecturer in several academia, a member of University management committee and promoter of several clinical programs in pediatric hematology and immunology. His current interests focus on biomarkers of individual response to immunomodulators.
Prof. Dan Atar
MD, Professor of Cardiology
Originally from Switzerland, Dr. Dan Atar, MD is a 1985 graduate from Basel University Medical School. He subsequently trained in internal medicine and cardiology. This was followed by stays abroad: at John Hopkins University in Baltimore (1991–1994) and the University of Copenhagen, where he worked as a senior cardiologist. From 1997 to 1998 Dr. Dan Atar served as senior physician at the University Hospital of Zurich. He became a cardiology junior faculty member under the guidance of Professor Thomas F. Lüscher, MD. In addition to clinical work Dr. Atar conducted experiments, investigating ischaemia and reperfusion of the heart. After serving as senior physician at the University of Copenhagen, he received a call in 2002 to a full professorship in cardiology at the University of Oslo, Norway, and was appointed head of the cardiology department at Aker University Hospital in Oslo. Here he worked with a large team of cardiologists and clinical researchers, especially in the field of cardiac markers, heart failure, and cardiovascular pharmacology. He is currently Head of Research at Oslo University Hospital Ulleval, Dept. of Medicine, and holds a full Professorship in Cardiology at the University of Oslo along with a Visiting Associate Professorship at the Johns Hopkins University in Baltimore, Maryland, USA. Prof. Atar served as Chairman of the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology and is Associated Editor of 'Cardiology' and 'The Heart Journal Cardiovascular Pharmacotherapy'. He co-authored more than 350 scientific articles and a number of ESC guidelines, such as the 2012 STEMI guideline and the 2010, 2012 and 2016 Atrial Fibrillation guideline. In 2016, he appeared on the prestigious Thompson-Reuters list of "The Most Cited Researchers of the World". Prof. Atar has been a member of Scientific Advisory Board at Serodus ASA since December 2015 and of ASAMEDIC since February 2016. For the last two years, he has served as Chairman of the Clinical Advisory Board at FIBREX Medical Inc., France.